Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) has shared an announcement.
Jiangsu Recbio Technology has received a filing notice from the China Securities Regulatory Commission approving the H share full circulation plan for 141,953,489 previously unlisted domestic shares held by 28 shareholders, with the filing valid for 12 months from 13 January 2026. The company plans to apply to the Hong Kong Stock Exchange for listing and trading of these converted H shares, a move that will increase its free float, enhance liquidity of its H shares and broaden participation by overseas investors, potentially strengthening its capital-market profile and flexibility for future financing.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$4.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a mainland China-based biopharmaceutical company listed in Hong Kong, focused on vaccine and related biotechnology R&D and commercialisation, with its share capital split between domestic shares and H shares targeting both onshore and international investors.
Average Trading Volume: 115,662
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.45B
Learn more about 2179 stock on TipRanks’ Stock Analysis page.